Prevence a léčba COVID-19
Année de publication: 2022
The presented clinical guideline is focused primarily on the treatment of COVID-19. It also deals with medicinal products that are not recommended for use, organ support, specifics of treatment in children and adolescents, multisystem inflammatory syndrome in children and adolescents (MIS-C, PIMS-TS), prevention of venous thromboembolism in COVID-19 patients, ethical aspects providing care in a situation of scarce resources and treating the post-covid syndrome.
The KDP is intended for:
all doctors who come into contact with persons suspected of having COVID-19 or who are already positive; to healthcare providers; to policy makers at the local and national level in the Czech Republic; to persons and organizations involved in COVID-19 research. The KDP was created by the method of adoption of the highest quality international recommendations available on the Live Map of recommendations about COVID-19 . The KDP currently contains 90 recommendations that were prepared and approved by the author's collective as of January 27, 2022. The KDP will be updated every three months or sooner as needed. You can share a link to a complete recommended procedure , a summary of recommendations , or from the "map" directly to individual recommendations in an interactive form.
cs|Předložený klinický doporučený postup je zaměřen primárně na léčbu COVID-19. Zabývá se také léčivými přípravky, které nejsou doporučené k použití, orgánovou podporou, specifiky léčby u dětí a mladistvých, multisystémovým zánětlivým syndromem u dětí a mladistvých (MIS-C, PIMS-TS), prevencí žilního tromboembolismu u COVID-19 pacientů, etickými aspekty poskytování péče v situaci nedostatku vzácných zdrojů a léčbou post-covidového syndromu.